AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17076980 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe monotherapy
Number of subjects: 86
Study 17076980 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam HCl plus ezetimibe
Number of subjects: 86
Study 17076980 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 86
Study 15555723 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-free amino acid drink (TFD)
Number of subjects: 13
Study 15555723 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 13
Study 11414672 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 15
Study 11414672 — intervention group
Group type: COMPARATOR
Intervention: Strength training
Number of subjects: 15
Study 9540024 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol (50, 100, 150, 200 mg t.i.d.)
Number of subjects: 385
Study 9540024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study 7972294 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular instant coffee
Number of subjects: 120
Study 7972294 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 120
Study 7972294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent regime (2 days decaff, 1 day caff)
Number of subjects: 120
Study 7972294 — intervention group
Group type: COMPARATOR
Intervention: Caffeine abstinence (general)
Number of subjects: 120
Study 7972294 — intervention group
Group type: COMPARATOR
Intervention: Caffeine treatment (overall)
Number of subjects: 120
Study 2585731 — intervention group
Group type: EXPERIMENTAL
Intervention: Second trial intervention based on LDH as a prognostic factor
Number of subjects: 79
Study 2585731 — intervention group
Group type: COMPARATOR
Intervention: First trial intervention
Number of subjects: 79
Study 1096904 — intervention group
Group type: EXPERIMENTAL
Intervention: Indometacin (100 g/day)
Number of subjects: 27
Study 1096904 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg/day)
Number of subjects: 27
Study 1096904 — intervention group
Group type: COMPARATOR
Intervention: Indometacin
Number of subjects: 27
Study 1096904 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 27
Study 31145798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 1859
Study 31145798 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg once daily
Number of subjects: 1859
Study 31145798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1859
Study 31145798 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1859
Study 29595683 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific tactile input (STI) stimuli according to the Vojta protocol (STI-group)
Number of subjects: 16
Study 29595683 — intervention group
Group type: COMPARATOR
Intervention: Non-STI stimulation (non-STI-group)
Number of subjects: 16
Study 26242289 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 122
Study 26242289 — intervention group
Group type: COMPARATOR
Intervention: Moderately fat-reduced diet
Number of subjects: 122
Study 26242289 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups
Number of subjects: 122
Study 25291960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-stand workstation
Number of subjects: 42
Study 25291960 — intervention group
Group type: COMPARATOR
Intervention: Control (waiting list)
Number of subjects: 42
Study 22228279 — intervention group
Group type: EXPERIMENTAL
Intervention: Provocative discography plus intradiscal injection of dexamethasone (5 mg)
Number of subjects: 45
Study 22228279 — intervention group
Group type: COMPARATOR
Intervention: Intridiscal injection of saline (placebo)
Number of subjects: 45
Study 20084586 — intervention group
Group type: EXPERIMENTAL
Intervention: New method of surfactant application
Number of subjects: 1541
Study 20084586 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1541
Study 17622942 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (Copaxone) immunotherapy
Number of subjects: 27
Study 17622942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 15683662 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam irradiation (EBI) 6 MV photons, total dose 24 Gy in six fractions in 2 weeks
Number of subjects: 60
Study 15683662 — intervention group
Group type: COMPARATOR
Intervention: Control group (no radiation therapy)
Number of subjects: 60
Study 15683662 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam irradiation (EBI)
Number of subjects: 60
Study 12095383 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (200 mg oral dose to women after onset of labor and 2 mg/kg oral dose to newborns between 48 and 72 hours after birth)
Number of subjects: 1270
Study 12095383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1270
Study 10073610 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 80
Study 10073610 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Number of subjects: 80
Study 10073610 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) with atherosclerotic disease
Number of subjects: 80
Study 10073610 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 80
Study 8700767 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement restoration (Ketac-Fil)
Number of subjects: 25
Study 2029180 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 23
Study 2029180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 6778337 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 0
Study 6778337 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy with concomitant myringotomy and tympanostomy tube insertion
Number of subjects: 0
Study 6778337 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 6607027 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin-trimethoprim (3.75:1)
Number of subjects: 747
Study 6607027 — intervention group
Group type: COMPARATOR
Intervention: Rifampin alone
Number of subjects: 747
Study 31474119 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention (6 messages per week for 6 months)
Number of subjects: 502
Study 31474119 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 502
Study 31474119 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care + 2 thank you messages per month)
Number of subjects: 502
Study 29700104 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 21
Study 29700104 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic CPAP
Number of subjects: 21
Study 27755050 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound support network (n = 32)
Number of subjects: 53
Study 27755050 — intervention group
Group type: COMPARATOR
Intervention: Standard organization of treatment (n = 21)
Number of subjects: 53
Study 24448006 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic bench stepping with arm movements
Number of subjects: 32
Study 24448006 — intervention group
Group type: COMPARATOR
Intervention: Aerobic bench stepping without arm movements
Number of subjects: 32
Study 22832540 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 23
Study 22832540 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 23
Study 19779025 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine orally disintegrating tablets (ODT) 10 mg o.d. for 8 days
Number of subjects: 10
Study 19779025 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine standard oral tablets (OST) 10 mg o.d. for 8 days
Number of subjects: 10
Study 19779025 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 10
Study 17687152 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg orally every morning for 7 days
Number of subjects: 142
Study 17687152 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally every morning for 7 days
Number of subjects: 142
Study 16326662 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR‐C training
Number of subjects: 95
Study 16326662 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study 14601011 — intervention group
Group type: EXPERIMENTAL
Intervention: Markov chain model of Lakatos
Number of subjects: 0
Study 10673975 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission-induction therapy followed by one consolidation course, with randomisation between autologous bone marrow transplantation (ABMT) and a second intensive consolidation course.
Number of subjects: 676
Study 10673975 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (alloBMT) for patients with a histocompatible sibling donor.
Number of subjects: 676
Study 10673975 — intervention group
Group type: EXPERIMENTAL
Intervention: Full protocol treatment completion.
Number of subjects: 676
Study 10673975 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rate at 6 years from diagnosis.
Number of subjects: 676
Study 8608488 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (GRA) 3 mg i.v.
Number of subjects: 117
Study 8608488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (OND) 24 mg i.v.
Number of subjects: 117
Study 8608488 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (TRO) 5 mg i.v.
Number of subjects: 117
Study 2012289 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine 0.75 ml.kg‐1 with morphine 0.05 mg.kg‐1
Number of subjects: 30
Study 2012289 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine 0.75 ml.kg‐1
Number of subjects: 30
Study 6128270 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of 16-phenoxy-omega-17,18,19,20-tetranor-PGE2 methyl sulphonylamide
Number of subjects: 295
Study 6128270 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg of 16-phenoxy-omega-17,18,19,20-tetranor-PGE2 methyl sulphonylamide
Number of subjects: 295
Study 31535560 — intervention group
Group type: EXPERIMENTAL
Intervention: advance care planning (survey, goals of care conversation, advance directive)
Number of subjects: 85
Study 31535560 — intervention group
Group type: COMPARATOR
Intervention: control (developmental history, safety tips, nutrition/exercise)
Number of subjects: 85
Study 31383503 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) program (20 weeks, 3 sessions/week, 4-8 exercises using free weights)
Number of subjects: 21
Study 31383503 — intervention group
Group type: COMPARATOR
Intervention: Control obesity (CO) group
Number of subjects: 21
Study 27044282 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned invasive treatment
Number of subjects: 1232
Study 27044282 — intervention group
Group type: COMPARATOR
Intervention: Planned conservative treatment
Number of subjects: 1232
Study 25887557 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine
Number of subjects: 100
Study 25887557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23376318 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injections (4 quadrant injections of 0.5 mL triamcinolone, 40 mg/mL, n = 29)
Number of subjects: 60
Study 23376318 — intervention group
Group type: COMPARATOR
Intervention: Saline (controls, n = 31)
Number of subjects: 60
Study 23376318 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injections
Number of subjects: 60
Study 23376318 — intervention group
Group type: COMPARATOR
Intervention: Saline (controls)
Number of subjects: 60
Study 20675729 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation in addition to conventional medical therapy
Number of subjects: 100
Study 20675729 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy alone
Number of subjects: 100
Study 19473600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg administered in a fed state (after a high-fat, high-calorie breakfast)
Number of subjects: 16
Study 19473600 — intervention group
Group type: COMPARATOR
Intervention: Fesoterodine 8 mg administered in a fasted state
Number of subjects: 16
Study 18039018 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical terbinafine (various formulations)
Number of subjects: 2899
Study 15491704 — intervention group
Group type: EXPERIMENTAL
Intervention: ProstaLund Feedback Treatment (PLFT)
Number of subjects: 154
Study 15491704 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 154
Study 12929060 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hemoclipping using a transparent cap
Number of subjects: 74
Study 12929060 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic hemoclipping without a transparent cap
Number of subjects: 74
Study 9888867 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g/d omega-3 fatty acids for 4 weeks
Number of subjects: 28
Study 9888867 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 28
Study 9888867 — intervention group
Group type: COMPARATOR
Intervention: 7 g/d omega-6 or omega-9 fatty acids for 4 weeks
Number of subjects: 28
Study 7718754 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat, 0.06 mg/kg
Number of subjects: 24
Study 7718754 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 24
Study 1851142 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha‐2a interferon (Roferon‐A) at a dose of 5 MU/m2 S.C. three times a week and cisplatinum at dose levels of 15, 20, 25, 33, and 42 mg/m2/week given intravenously
Number of subjects: 18
Study 6782467 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 12
Study 6782467 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 12
Study 30375028 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention in primary health care (PHC)
Number of subjects: 150
Study 30375028 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 150
Study 29537978 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal rivastigmine (9.5 mg/10 cm daily)
Number of subjects: 19
Study 29537978 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rivastigmine (6 mg twice daily)
Number of subjects: 19
Study 29537978 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal rivastigmine
Number of subjects: 19
Study 29537978 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rivastigmine
Number of subjects: 19
Study 29537978 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 19
Study 26507721 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg dose
Number of subjects: 0
Study 26507721 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 0
Study 24326741 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg/day
Number of subjects: 364
Study 24326741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study 22748098 — intervention group
Group type: EXPERIMENTAL
Intervention: XELIRI-bevacizumab (irinotecan, capecitabine, bevacizumab, every 3 weeks)
Number of subjects: 285
Study 22748098 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI-bevacizumab (irinotecan, leucovorin, fluorouracil, bevacizumab, every 2 weeks)
Number of subjects: 285
Study 22748098 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 285
Study 21077306 — intervention group
Group type: EXPERIMENTAL
Intervention: BPB with 0.2% ropivacaine at an infusion rate of 6 ml x hr(‐1) (n = 12)
Number of subjects: 39
Study 21077306 — intervention group
Group type: EXPERIMENTAL
Intervention: BPB with 0.2% ropivacaine at an infusion rate of 4 ml x hr(‐1) (n = 12)
Number of subjects: 39
Study 21077306 — intervention group
Group type: COMPARATOR
Intervention: Control group (no continuous BPB, n = 10)
Number of subjects: 39
Study 21077306 — intervention group
Group type: EXPERIMENTAL
Intervention: BPB with 0.2% ropivacaine at an infusion rate of 8 ml x hr(‐1) (n = 5)
Number of subjects: 39
Study 18197883 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based behavioural training (BT)
Number of subjects: 108
Study 18197883 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control group (WLC)
Number of subjects: 108
Study 15906030 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cycles of chemotherapy prior to surgery and three cycles after surgery (Group 1)
Number of subjects: 24
Study 15906030 — intervention group
Group type: EXPERIMENTAL
Intervention: Six cycles of chemotherapy prior to surgery (Group 2)
Number of subjects: 24
Study 15906030 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (six cycles)
Number of subjects: 24
Study 12923506 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbst appliance
Number of subjects: 215
Study 12923506 — intervention group
Group type: COMPARATOR
Intervention: Twin-block appliance
Number of subjects: 215
Study 10505539 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin (0.4 mg/kg bolus, then 0.15 mg/kg per hour infusion)
Number of subjects: 10141
Study 10505539 — intervention group
Group type: COMPARATOR
Intervention: Heparin (5,000-U bolus, then 15-U/kg per hour infusion)
Number of subjects: 10141
Study 10505539 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 10141
Study 10505539 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 10141
Study 8853213 — intervention group
Group type: EXPERIMENTAL
Intervention: Amesergide
Number of subjects: 8
Study 8853213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1346818 — intervention group
Group type: COMPARATOR
Intervention: BCG vaccine
Number of subjects: 29113
Study 1346818 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG plus 6 x 10(8) irradiated, autoclaved M leprae
Number of subjects: 29113
Study 1346818 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG plus M leprae
Number of subjects: 29113
Study 6374402 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lithium started at the time of biopsy‐proven hypoplasia
Number of subjects: 35
Study 6374402 — intervention group
Group type: COMPARATOR
Intervention: No lithium
Number of subjects: 35
Study 30536081 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 250 μg daily
Number of subjects: 15
Study 30536081 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 100 μg daily
Number of subjects: 15
Study 30536081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31256137 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Motion Simulation (TMSim)
Number of subjects: 120
Study 31256137 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 120
Study 31256137 — intervention group
Group type: EXPERIMENTAL
Intervention: TMSim + WBV
Number of subjects: 120
Study 30239794 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 1778
Study 30239794 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy
Number of subjects: 1778
Study 24473106 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring letters intervention
Number of subjects: 0
Study 23137494 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod (GW856553)
Number of subjects: 535
Study 23137494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study 20485147 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed (37 degrees C), humidified (98% RH) insufflation carbon dioxide
Number of subjects: 82
Study 20485147 — intervention group
Group type: COMPARATOR
Intervention: Standard gas (19 degrees C, 0% RH)
Number of subjects: 82
Study 18556964 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) at a dosage of 0.067 mg/kg/day
Number of subjects: 0
Study 16087818 — intervention group
Group type: EXPERIMENTAL
Intervention: Full starting dose of levothyroxine (1.6 mug/kg)
Number of subjects: 75
Study 16087818 — intervention group
Group type: COMPARATOR
Intervention: Low starting dose of levothyroxine (25 mug, increased every 4 weeks)
Number of subjects: 75
Study 12452231 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 1 mg and droperidol 0.0625 mg
Number of subjects: 94
Study 12452231 — intervention group
Group type: COMPARATOR
Intervention: Morphine 1 mg
Number of subjects: 94
Study 10358538 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised protocol administered by senior nurses
Number of subjects: 0
Study 10358538 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7807658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 875
Study 7807658 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE), 0.625 mg/d
Number of subjects: 875
Study 7807658 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE, 0.625 mg/d plus cyclic medroxyprogesterone acetate (MPA), 10 mg/d for 12 d/mo
Number of subjects: 875
Study 7807658 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE, 0.625 mg/d plus consecutive MPA, 2.5 mg/d
Number of subjects: 875
Study 7807658 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE, 0.625 mg/d plus cyclic micronized progesterone (MP), 200 mg/d for 12 d/mo
Number of subjects: 875
Study 8369511 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (prednisone, 60 mg/day for 7 days, followed by tapering over 14 days)
Number of subjects: 23
Study 8369511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 8369511 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 23
Study 2947465 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide
Number of subjects: 261
Study 2947465 — intervention group
Group type: COMPARATOR
Intervention: metaproterenol
Number of subjects: 261
Study 29792226 — intervention group
Group type: EXPERIMENTAL
Intervention: Tree Theme Method® (TTM)
Number of subjects: 118